839 reports of this reaction
1.4% of all THALIDOMIDE reports
#18 most reported adverse reaction
DEEP VEIN THROMBOSIS is the #18 most commonly reported adverse reaction for THALIDOMIDE, manufactured by Celgene Corporation. There are 839 FDA adverse event reports linking THALIDOMIDE to DEEP VEIN THROMBOSIS. This represents approximately 1.4% of all 58,680 adverse event reports for this drug.
THALIDOMIDE has an overall safety score of 95 out of 100. Patients taking THALIDOMIDE who experience deep vein thrombosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEEP VEIN THROMBOSIS is a less commonly reported adverse event for THALIDOMIDE, but still significant enough to appear in the safety profile.
In addition to deep vein thrombosis, the following adverse reactions have been reported for THALIDOMIDE:
The following drugs have also been linked to deep vein thrombosis in FDA adverse event reports:
DEEP VEIN THROMBOSIS has been reported as an adverse event in 839 FDA reports for THALIDOMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEEP VEIN THROMBOSIS accounts for approximately 1.4% of all adverse event reports for THALIDOMIDE, making it a notable side effect.
If you experience deep vein thrombosis while taking THALIDOMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.